Axis NIFTY Healthcare ETF

A Equity ETF scheme from Axis Mutual Fund. Figures below are for the Regular · option not stated plan (ISIN INF846K01Z12).

NAV ₹174.6559 on 16 November 2026.

Expense ratio

Total expense ratio 0.45% a year for the Regular · option not stated plan, as AMFI published it on 28 October 2026: base expense ratio 0.33%, brokerage 0.01%, transaction costs 0.00%, statutory levies including GST 0.11%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year15.8%14.4%-9.2%0.610.66
3 years20.9%14.8%-15.7%0.940.93
5 years14.6%15.0%-18.4%0.510.52

Too little NAV history for the 10-year figures.

Not ranked in its category: its category mixes funds too different to rank against one another.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 100.0% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 16.32%
  2. Divi's Laboratories Limited — 10.78%
  3. Laurus Labs Limited — 8.12%
  4. Apollo Hospitals Enterprise Limited — 7.54%
  5. Dr. Reddy's Laboratories Limited — 7.15%
  6. Cipla Limited — 6.73%
  7. Torrent Pharmaceuticals Limited — 5.89%
  8. Max Healthcare Institute Limited — 5.55%
  9. Lupin Limited — 4.24%
  10. Aurobindo Pharma Limited — 4.03%

Plans

Other funds in Equity ETF

All 86 funds in Equity ETF · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.